Allison M Lytle
Overview
Explore the profile of Allison M Lytle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zoine J, Prince C, Story J, Branella G, Lytle A, Fedanov A, et al.
Gene Ther
. 2021 Aug;
29(5):1-12.
PMID: 34385604
While targeting CD19+ hematologic malignancies with CAR T cell therapy using single chain variable fragments (scFv) has been highly successful, novel strategies for applying CAR T cell therapy with other...
2.
Tran R, Myers D, Denning G, Shields J, Lytle A, Alrowais H, et al.
Mol Ther
. 2017 Aug;
25(10):2372-2382.
PMID: 28780274
Ex vivo gene therapy using lentiviral vectors (LVs) is a proven approach to treat and potentially cure many hematologic disorders and malignancies but remains stymied by cumbersome, cost-prohibitive, and scale-limited...
3.
Lytle A, Brown H, Paik N, Knight K, Wright J, Spencer H, et al.
Mol Ther Methods Clin Dev
. 2016 Feb;
3:15056.
PMID: 26909355
Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness...
4.
Brown H, Wright J, Zhou S, Lytle A, Shields J, Spencer H, et al.
Mol Ther Methods Clin Dev
. 2015 May;
1:14036.
PMID: 26015976
Clinical data support the feasibility and safety of adeno-associated viral (AAV) vectors in gene therapy applications. Despite several clinical trials of AAV-based gene transfer for hemophilia B, a unique set...